Dependence	O
of	O
Intestinal	B:C0021826
Absorption	I:C0021826
Profile	O
of	O
Insulin	O
on	O
Carrier	O
Morphology	O
Composed	O
of	O
β-	O
Cyclodextrin	I:C0013161
-	I:C0013161
Grafted	I:C0013161
Chitosan	I:C0013161

Dependence	O
of	O
Intestinal	O
Absorption	I:C0021826
Profile	O
of	O
Insulin	B:C0021641
on	O
Carrier	O
Morphology	O
Composed	O
of	O
β-	O
Cyclodextrin	I:C0013161
-	I:C0013161
Grafted	I:C0013161
Chitosan	I:C0013161

Dependence	O
of	O
Intestinal	O
Absorption	I:C0021826
Profile	O
of	O
Insulin	O
on	O
Carrier	B:C0013161
Morphology	O
Composed	O
of	O
β-	O
Cyclodextrin	I:C0013161
-	I:C0013161
Grafted	I:C0013161
Chitosan	I:C0013161

Dependence	O
of	O
Intestinal	O
Absorption	I:C0021826
Profile	O
of	O
Insulin	O
on	O
Carrier	O
Morphology	O
Composed	O
of	O
β-	B:C0013161
Cyclodextrin	I:C0013161
-	I:C0013161
Grafted	I:C0013161
Chitosan	I:C0013161

The	O
effect	O
of	O
carrier	B:C0013161
morphology	O
on	O
the	O
intestinal	O
absorption	I:C0021826
of	O
insulin	O
was	O
investigated	O
using	O
a	O
morphology	O
-	I:C0013161
tunable	I:C0013161
polymeric	I:C0013161
carrier	I:C0013161
,	O
β-	O
cyclodextrin	I:C0013161
-	I:C0013161
grafted	I:C0013161
chitosan	I:C0013161
(	O
BCC	O
)	O
.	O

The	O
effect	O
of	O
carrier	O
morphology	O
on	O
the	O
intestinal	B:C0021826
absorption	I:C0021826
of	O
insulin	O
was	O
investigated	O
using	O
a	O
morphology	O
-	I:C0013161
tunable	I:C0013161
polymeric	I:C0013161
carrier	I:C0013161
,	O
β-	O
cyclodextrin	I:C0013161
-	I:C0013161
grafted	I:C0013161
chitosan	I:C0013161
(	O
BCC	O
)	O
.	O

The	O
effect	O
of	O
carrier	O
morphology	O
on	O
the	O
intestinal	O
absorption	I:C0021826
of	O
insulin	B:C0021641
was	O
investigated	O
using	O
a	O
morphology	O
-	I:C0013161
tunable	I:C0013161
polymeric	I:C0013161
carrier	I:C0013161
,	O
β-	O
cyclodextrin	I:C0013161
-	I:C0013161
grafted	I:C0013161
chitosan	I:C0013161
(	O
BCC	O
)	O
.	O

The	O
effect	O
of	O
carrier	O
morphology	O
on	O
the	O
intestinal	O
absorption	I:C0021826
of	O
insulin	O
was	O
investigated	O
using	O
a	O
morphology	B:C0013161
-	I:C0013161
tunable	I:C0013161
polymeric	I:C0013161
carrier	I:C0013161
,	O
β-	O
cyclodextrin	I:C0013161
-	I:C0013161
grafted	I:C0013161
chitosan	I:C0013161
(	O
BCC	O
)	O
.	O

The	O
effect	O
of	O
carrier	O
morphology	O
on	O
the	O
intestinal	O
absorption	I:C0021826
of	O
insulin	O
was	O
investigated	O
using	O
a	O
morphology	O
-	I:C0013161
tunable	I:C0013161
polymeric	I:C0013161
carrier	I:C0013161
,	O
β-	B:C0013161
cyclodextrin	I:C0013161
-	I:C0013161
grafted	I:C0013161
chitosan	I:C0013161
(	O
BCC	O
)	O
.	O

The	O
effect	O
of	O
carrier	O
morphology	O
on	O
the	O
intestinal	O
absorption	I:C0021826
of	O
insulin	O
was	O
investigated	O
using	O
a	O
morphology	O
-	I:C0013161
tunable	I:C0013161
polymeric	I:C0013161
carrier	I:C0013161
,	O
β-	O
cyclodextrin	I:C0013161
-	I:C0013161
grafted	I:C0013161
chitosan	I:C0013161
(	O
BCC	B:C0013161
)	O
.	O

The	O
insulin	B:C0021641
-	O
BCC	O
complexes	O
were	O
prepared	O
in	O
either	O
acetate	O
or	O
citrate	O
buffer	O
solutions	O
,	O
followed	O
by	O
dilution	O
with	O
phosphate	O
buffer	O
for	O
the	O
administration	O
.	O

The	O
insulin	O
-	O
BCC	B:C0013161
complexes	O
were	O
prepared	O
in	O
either	O
acetate	O
or	O
citrate	O
buffer	O
solutions	O
,	O
followed	O
by	O
dilution	O
with	O
phosphate	O
buffer	O
for	O
the	O
administration	O
.	O

The	O
insulin	O
-	O
BCC	O
complexes	B:C1704241
were	O
prepared	O
in	O
either	O
acetate	O
or	O
citrate	O
buffer	O
solutions	O
,	O
followed	O
by	O
dilution	O
with	O
phosphate	O
buffer	O
for	O
the	O
administration	O
.	O

The	O
insulin	O
-	O
BCC	O
complexes	O
were	O
prepared	O
in	O
either	O
acetate	O
or	O
citrate	O
buffer	O
solutions	O
,	O
followed	O
by	O
dilution	B:C0079240
with	O
phosphate	O
buffer	O
for	O
the	O
administration	O
.	O

The	O
insulin	O
-	O
BCC	O
complexes	O
were	O
prepared	O
in	O
either	O
acetate	O
or	O
citrate	O
buffer	O
solutions	O
,	O
followed	O
by	O
dilution	O
with	O
phosphate	O
buffer	O
for	O
the	O
administration	B:C1533734
.	O

The	O
complex	B:C1704241
had	O
a	O
molecular	O
network	I:C0220807
structure	I:C0220807
in	O
the	O
acetate	O
buffer	O
,	O
whereas	O
nanoparticles	O
formed	O
in	O
the	O
citrate	O
buffer	O
.	O

The	O
complex	O
had	O
a	O
molecular	B:C0220807
network	I:C0220807
structure	I:C0220807
in	O
the	O
acetate	O
buffer	O
,	O
whereas	O
nanoparticles	O
formed	O
in	O
the	O
citrate	O
buffer	O
.	O

The	O
network	B:C0220807
structure	I:C0220807
in	O
the	O
acetate	O
buffer	O
was	O
maintained	O
even	O
after	O
dilution	O
with	O
a	O
phosphate	O
buffer	O
,	O
but	O
the	O
nanoparticles	O
in	O
the	O
citrate	O
buffer	O
caused	O
aggregation	O
after	O
dilution	O
.	O

The	O
network	O
structure	I:C0220807
in	O
the	O
acetate	O
buffer	O
was	O
maintained	O
even	O
after	O
dilution	B:C0079240
with	O
a	O
phosphate	O
buffer	O
,	O
but	O
the	O
nanoparticles	O
in	O
the	O
citrate	O
buffer	O
caused	O
aggregation	O
after	O
dilution	O
.	O

The	O
network	O
structure	I:C0220807
in	O
the	O
acetate	O
buffer	O
was	O
maintained	O
even	O
after	O
dilution	O
with	O
a	O
phosphate	O
buffer	O
,	O
but	O
the	O
nanoparticles	O
in	O
the	O
citrate	O
buffer	O
caused	O
aggregation	O
after	O
dilution	B:C0079240
.	O

Both	O
complexes	B:C1704241
enhanced	O
the	O
intestinal	O
absorption	I:C0021826
of	O
insulin	O
.	O

Both	O
complexes	O
enhanced	O
the	O
intestinal	B:C0021826
absorption	I:C0021826
of	O
insulin	O
.	O

Both	O
complexes	O
enhanced	O
the	O
intestinal	O
absorption	I:C0021826
of	O
insulin	B:C0021641
.	O

Interestingly	O
,	O
their	O
absorption	B:C0021826
profiles	O
were	O
totally	O
different	O
;	O
prompt	O
absorption	O
was	O
observed	O
for	O
the	O
complex	O
prepared	O
in	O
acetate	O
buffer	O
,	O
whereas	O
sustained	O
absorption	O
was	O
observed	O
for	O
the	O
complex	O
prepared	O
in	O
citrate	O
buffer	O
.	O

Interestingly	O
,	O
their	O
absorption	O
profiles	O
were	O
totally	O
different	O
;	O
prompt	O
absorption	B:C0021826
was	O
observed	O
for	O
the	O
complex	O
prepared	O
in	O
acetate	O
buffer	O
,	O
whereas	O
sustained	O
absorption	O
was	O
observed	O
for	O
the	O
complex	O
prepared	O
in	O
citrate	O
buffer	O
.	O

Interestingly	O
,	O
their	O
absorption	O
profiles	O
were	O
totally	O
different	O
;	O
prompt	O
absorption	O
was	O
observed	O
for	O
the	O
complex	B:C1704241
prepared	O
in	O
acetate	O
buffer	O
,	O
whereas	O
sustained	O
absorption	O
was	O
observed	O
for	O
the	O
complex	O
prepared	O
in	O
citrate	O
buffer	O
.	O

Interestingly	O
,	O
their	O
absorption	O
profiles	O
were	O
totally	O
different	O
;	O
prompt	O
absorption	O
was	O
observed	O
for	O
the	O
complex	O
prepared	O
in	O
acetate	O
buffer	O
,	O
whereas	O
sustained	O
absorption	B:C0021826
was	O
observed	O
for	O
the	O
complex	O
prepared	O
in	O
citrate	O
buffer	O
.	O

Interestingly	O
,	O
their	O
absorption	O
profiles	O
were	O
totally	O
different	O
;	O
prompt	O
absorption	O
was	O
observed	O
for	O
the	O
complex	O
prepared	O
in	O
acetate	O
buffer	O
,	O
whereas	O
sustained	O
absorption	O
was	O
observed	O
for	O
the	O
complex	B:C1704241
prepared	O
in	O
citrate	O
buffer	O
.	O

The	O
difference	O
in	O
the	O
absorption	B:C0021826
patterns	O
was	O
attributed	O
to	O
the	O
difference	O
in	O
the	O
complex	O
morphology	O
.	O

The	O
difference	O
in	O
the	O
absorption	O
patterns	O
was	O
attributed	O
to	O
the	O
difference	O
in	O
the	O
complex	B:C1704241
morphology	O
.	O

Next	O
,	O
penetratin	B:C0961324
,	O
a	O
cell	O
-	I:C2936243
penetrating	I:C2936243
peptide	I:C2936243
,	O
was	O
grafted	O
to	O
BCC	O
to	O
find	O
further	O
improvement	O
in	O
the	O
absorption	O
behavior	O
.	O

Next	O
,	O
penetratin	O
,	O
a	O
cell	B:C2936243
-	I:C2936243
penetrating	I:C2936243
peptide	I:C2936243
,	O
was	O
grafted	O
to	O
BCC	O
to	O
find	O
further	O
improvement	O
in	O
the	O
absorption	O
behavior	O
.	O

Next	O
,	O
penetratin	O
,	O
a	O
cell	O
-	I:C2936243
penetrating	I:C2936243
peptide	I:C2936243
,	O
was	O
grafted	O
to	O
BCC	B:C0013161
to	O
find	O
further	O
improvement	O
in	O
the	O
absorption	O
behavior	O
.	O

Next	O
,	O
penetratin	O
,	O
a	O
cell	O
-	I:C2936243
penetrating	I:C2936243
peptide	I:C2936243
,	O
was	O
grafted	O
to	O
BCC	O
to	O
find	O
further	O
improvement	O
in	O
the	O
absorption	B:C0021826
behavior	O
.	O

A	O
simple	O
mixture	O
of	O
penetratin	B:C0961324
and	O
BCC	O
was	O
also	O
effective	O
.	O

A	O
simple	O
mixture	O
of	O
penetratin	O
and	O
BCC	B:C0013161
was	O
also	O
effective	O
.	O

An	O
oral	B:C0001563
administration	I:C0001563
study	O
was	O
also	O
conducted	O
in	O
mice	O
to	O
observe	O
effective	O
suppression	O
of	O
glucose	O
levels	I:C0428548
,	O
which	O
was	O
further	O
enhanced	O
by	O
coadministration	O
of	O
penetratin	O
.	O

An	O
oral	O
administration	I:C0001563
study	O
was	O
also	O
conducted	O
in	O
mice	B:C0026809
to	O
observe	O
effective	O
suppression	O
of	O
glucose	O
levels	I:C0428548
,	O
which	O
was	O
further	O
enhanced	O
by	O
coadministration	O
of	O
penetratin	O
.	O

An	O
oral	O
administration	I:C0001563
study	O
was	O
also	O
conducted	O
in	O
mice	O
to	O
observe	O
effective	O
suppression	O
of	O
glucose	B:C0428548
levels	I:C0428548
,	O
which	O
was	O
further	O
enhanced	O
by	O
coadministration	O
of	O
penetratin	O
.	O

An	O
oral	O
administration	I:C0001563
study	O
was	O
also	O
conducted	O
in	O
mice	O
to	O
observe	O
effective	O
suppression	O
of	O
glucose	O
levels	I:C0428548
,	O
which	O
was	O
further	O
enhanced	O
by	O
coadministration	B:C1533734
of	O
penetratin	O
.	O

An	O
oral	O
administration	I:C0001563
study	O
was	O
also	O
conducted	O
in	O
mice	O
to	O
observe	O
effective	O
suppression	O
of	O
glucose	O
levels	I:C0428548
,	O
which	O
was	O
further	O
enhanced	O
by	O
coadministration	O
of	O
penetratin	B:C0961324
.	O

Thus	O
,	O
BCC	B:C0013161
was	O
proven	O
to	O
be	O
an	O
effective	O
carrier	O
for	O
enhancing	O
oral	O
absorption	O
of	O
peptide	O
drugs	O
,	O
and	O
it	O
is	O
suggested	O
that	O
the	O
carrier	O
morphology	O
is	O
also	O
an	O
important	O
factor	O
that	O
influences	O
the	O
absorption	O
profile	O
.	O

Thus	O
,	O
BCC	O
was	O
proven	O
to	O
be	O
an	O
effective	O
carrier	B:C0013161
for	O
enhancing	O
oral	O
absorption	O
of	O
peptide	O
drugs	O
,	O
and	O
it	O
is	O
suggested	O
that	O
the	O
carrier	O
morphology	O
is	O
also	O
an	O
important	O
factor	O
that	O
influences	O
the	O
absorption	O
profile	O
.	O

Thus	O
,	O
BCC	O
was	O
proven	O
to	O
be	O
an	O
effective	O
carrier	O
for	O
enhancing	O
oral	B:C0226896
absorption	O
of	O
peptide	O
drugs	O
,	O
and	O
it	O
is	O
suggested	O
that	O
the	O
carrier	O
morphology	O
is	O
also	O
an	O
important	O
factor	O
that	O
influences	O
the	O
absorption	O
profile	O
.	O

Thus	O
,	O
BCC	O
was	O
proven	O
to	O
be	O
an	O
effective	O
carrier	O
for	O
enhancing	O
oral	O
absorption	O
of	O
peptide	B:C0030956
drugs	O
,	O
and	O
it	O
is	O
suggested	O
that	O
the	O
carrier	O
morphology	O
is	O
also	O
an	O
important	O
factor	O
that	O
influences	O
the	O
absorption	O
profile	O
.	O

Thus	O
,	O
BCC	O
was	O
proven	O
to	O
be	O
an	O
effective	O
carrier	O
for	O
enhancing	O
oral	O
absorption	O
of	O
peptide	O
drugs	B:C1254351
,	O
and	O
it	O
is	O
suggested	O
that	O
the	O
carrier	O
morphology	O
is	O
also	O
an	O
important	O
factor	O
that	O
influences	O
the	O
absorption	O
profile	O
.	O

Thus	O
,	O
BCC	O
was	O
proven	O
to	O
be	O
an	O
effective	O
carrier	O
for	O
enhancing	O
oral	O
absorption	O
of	O
peptide	O
drugs	O
,	O
and	O
it	O
is	O
suggested	O
that	O
the	O
carrier	B:C0013161
morphology	O
is	O
also	O
an	O
important	O
factor	O
that	O
influences	O
the	O
absorption	O
profile	O
.	O

Thus	O
,	O
BCC	O
was	O
proven	O
to	O
be	O
an	O
effective	O
carrier	O
for	O
enhancing	O
oral	O
absorption	O
of	O
peptide	O
drugs	O
,	O
and	O
it	O
is	O
suggested	O
that	O
the	O
carrier	O
morphology	O
is	O
also	O
an	O
important	O
factor	O
that	O
influences	O
the	O
absorption	B:C0021826
profile	O
.	O

